Results 41 to 50 of about 8,656 (193)
Ожирение и метаболизм, 2009 Insulin resistance in muscle and liver and β-cell failure represent the core pathophysiologic defects in type 2 diabetes. Now it isrecognized that the β-cell failure occurs much earlier and is more severe than previously thought. As a result, earlier and
doaj +1 more source
Hypoglycemia episodes after biliopancreatic diversion for morbid obesity: clinical case presentation
Ожирение и метаболизм, 2013 Modifications of glucose metabolism are observed after bariatric surgery and are attributed to the increased release of incretins – biologically active gut peptides.
doaj +1 more source
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [PDF]
Diabetes & Metabolism Journal, 2019 BackgroundBased on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs on major adverse cardiovascular events (MACEs) and ...
Yu Mi Kang +8 more
doaj +1 more source
Understanding the Incretin Effect [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2011 It is well known that the incretin effect contributes as much as half of the insulin secretory response to oral glucose load and that this effect is reduced along with worsening glucose tolerance in those with type 2 diabetes. Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from ...
openaire +2 more sources
Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects [PDF]
, 2019 AimIncretins [dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide 1 RA (GLP-1 RA)] and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) groups are now routinely used for type 2 diabetes therapy and comprise a large number of medicinal
Manoela Manova +9 more
core +1 more source
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
, 2013 We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced co-agonism at both of the receptors for the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Hofmann, S. +32 more
core +2 more sources
Сахарный диабет, 2011 Type 2 diabetes mellitus is a disease in which traditional therapeutic strategies, such as optimization of the lifestyle, intake of metformin and sulfonylureasor glitazone prove secondarily inefficient in the short run.
Elena Nikolaevna Trunina +2 more
doaj +1 more source
The incretin concept today [PDF]
Diabetologia, 1979 1. The insulinogenic factor of the gastrointestinal mucosa named "incretin" is only one part of the complex enteroinsular axis. --2. Of the chemically defined gastrointestinal hormones GIP is the strongest incretin candidate. --3. Because of the dual function of GIP as gastrone and insulinotropic substance several safeguards against GIP-mediated ...
openaire +2 more sources
The entero-insular axis in type 2 diabetes - incretins as therapeutic agents
, 2001 The search for intestinal factors regulating the endocrine secretion of the pancreas started soon after the discovery of secretin, i.e. nearly 100 years ago.
Creutzfeldt, W., W. Creutzfeldt
core +1 more source
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
Сахарный диабет, 2011 Type 2 diabetes mellitus (T2 DM) is often seen in patients with obesity. Bariatric surgery, aimed to decrease body weight, can often help those patientsto improve glycemic status.
Ekaterina Alekseevna Shestakova
doaj +1 more source